*Promoted by Sica Media

📈 Join us for LIVE TRADING action all day long in the 📈

 Market Master’s trading room

We’ll talk about today’s focus stock, my Gamma Trigger at 1pm EST and dozens of other breaking stocks that are moving during the day.

The markets look like they will be under pressure again today.  I think this is going to be the theme for a while now.

If you joined me, you saw that I made the call to go short QQQ’s in my live session on Tuesday, before yesterday’s drop.

I really hate to short tech stocks, but my “Gamma Trigger” indicators were all signaling that we are near a short-term top in the market.  I’m going to talk all about this today in a special presentation at 1pm ESTPlease join me. 

Now, just because the overall market might be stalling out doesn’t mean there aren’t still great opportunities out there, just like the last small stock I brought to your attention on Tuesday.

If you paid attention to that idea, you saw back-to-back days when the stock gained 10%.

Not bad at all, right?!

In fact, in a down market, I think some stocks become so “oversold” that they become incredible risk/reward plays.

That is what I think I have for you today.

I have been following a small biotech company for a long time, and I think right now is a crucial time to revisit it.

I want you to pull up Coeptis Therapeutics Holdings (COEP) on your platform right away.

When you look at the price chart, I want you to pay attention to this Gamma Trigger reversal pattern to the upside (I saw the exact opposite when I made the call to go short QQQ on Tuesday)

Now, even if you are not a professional technical analyst, I think this is a pretty easy move to spot.

Right now, we have a tiny stock that had a big drop, made a base for over a week and has started to break out to the upside.

I find it strange that weaker stocks sometimes have a tendency to bounce in poor market conditions.  Maybe it is because short sellers cover their positions and move on on to new targets?   

Whatever the reason is, I think it is pretty obvious that COEP has been making a move out of the oversold zone lately.

While it is very early in the move, I think it is the perfect time to start watching this again.

If this trend continues, COEP has a lot of room to run before it would even touch the levels we just saw in March.

One of the things I love about smaller stocks is the percentage moves they can make on the way up (or down).

For example, if COEP moves just a dime right now, that is more than a 25% move!

This is a volatile stock, so approach it accordingly. Come prepared with a game plan that makes sense for you — and stick to it!

I think this has all of the catalysts for what could be an explosive move soon, so it really needs to be top on your list to watch today.

The trading opportunity is awesome, but if you’re not familiar with the business, I think you should spend some time getting to know more about them.

Coeptis Therapeutics Holdings, Inc. (COEP) is a clinical-stage biopharma company based in Wexford, PA, that’s on a bold mission to revolutionize therapies for cancer, respiratory viruses, and autoimmune conditions.

Fun fact: I was an pre-IPO investor in COEP!

While I don’t have any shares now, I invested in this company prior to when they were listed on the Nasdaq last year.  I have been keeping a close eye on their development since.

At the core of COEP’s pipeline is an attempt to pioneer new treatments using cell therapy.

According to trusty-old Wikipedia, cell therapy is:

a therapy in which viable cells are injected, grafted or implanted into a patient in order to effectuate a medicinal effect, for example, by transplanting T-cells capable of fighting cancer cells via cell-mediated immunity in the course of immunotherapy, or grafting stem cells to regenerate diseased tissues.

These cutting-edge treatments are potentially very lucrative.

Precedence Research has stated: “The global cell therapy market was valued at US $10.35 billion in 2021, and it is expected to hit US $60.67 billion by 2030.”

That’s a nearly 500% increase in less than a decade.

From a business standpoint, COEP is barking up the right tree.

One of the core technologies the company hopes to tap those billions with is known as SNAP-CAR, which COEP licensed and acquired from the University of Pittsburgh in 2022.

The “CAR” part of the name refers to “chimeric antigen receptor” T-cell therapy, which is a relatively new cancer treatment that genetically engineers immune cells to target and destroy cancer cells. You can read more about CAR-T therapy here.

COEP believes its SNAP-CAR technology will improve on existing therapies in several ways.

Current CAR-T therapies require cells to be pulled from the patient or a donor, modified, and then readministered to the patient — a difficult and expensive process.

If SNAP-CAR works the way the company hopes it will, doctors will be able to use the same “universal” cell to attack many different cancers at multiple points along the cancer cells.

The company initially set out to use SNAP-CAR to target cancer — and it is still pursuing those treatments — but it recently expanded its sights.

COEP announced in February that it would be starting a Phase 2 trial to investigate its therapy as an antiviral to go after the “tripledemic” of influenza, COVID-19 and respiratory syncytial virus (RSV).

Later that month, it announced it would be exploring the therapy’s potential to impact autoimmune diseases such as lupus, arthritis, and multiple sclerosis.

“We remain committed to developing these remarkable technologies as treatments for various indications across oncology… however we also recognize the enormous potential for these platform technologies to address and possibly revolutionize the treatment landscape of autoimmune diseases,” commented CEO Dave Mehalick.

Spend time right now doing your own research on the stock, and of course, always approach your trading in a responsible manner. Trading is very risky and nothing is ever guaranteed, so never trade with more than you can afford to lose, and always have a well-thought-out game plan that takes your personal risk tolerance into consideration.

Bottom line: I love the short-term opportunities that tiny stocks can provide when you catch them at the right time. I think COEP has all of the pieces in place right now that could set it up for a “bottom bounce” play today.

These types of moves happen fast (in both directions) so make sure you are keeping a close eye on COEP right away!

To Your Success,

Jeff Bishop

👊 Make sure you are getting my mobile text alerts –  text “RAGE” to 1-(888) 404-5747 to get all of my latest HOT STOCK ideas delivered right to your phone (make sure you put the “1” at the front!).  Don’t miss out!

*Sponsored content/paid advertisement. This investment involves substantial risk. Please read our full disclosure below for a detailed discussion of risks and atypical results.



*PAID ADVERTISEMENT. Currently, RagingBull was paid twelve thousand five hundred dollars by ach bank transfer by Sica Media for advertising Coeptis from for a one day period on april 11, 2024 . RagingBull has previously been paid fifteen thousand dollars by ach bank transfer by Coeptis Therapeutics Holdings, Inc from a period beginning on December 13, 2023 through December 15 of the same year.  Previously, RagingBull was paid nineteen thousand dollars by ach bank transfer by Lifewater Media for advertising Coeptis from a period beginning on June 7, 2023 through June 8 of the same year. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of Coeptis Therapeutics Holdings, Inc, increased trading volume, and possibly an increased share price of Coeptis Therapeutics Holdings, Inc’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in Coeptis Therapeutics Holdings, Inc, though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication.

SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions, and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments.

Our reports/releases are a commercial advertisement and are for general information purposes ONLY. A portion of our business is engaged in the marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use. A portion of RagingBull’s business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, SMS, push notifications. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Frequently, companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the corporate awareness program ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct.

TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied.

NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.

USE OF FORWARD-LOOKING STATEMENTS. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https: // www. Sec. gov/ edgar/searchedgar /companysearch

FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for educational and informational purposes only. All material information contained in this advertisement is based on information generally available to the public, which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision.